Seeking Alpha

Credit Suisse thinks investors are overlooking the potential of Merck's (MRK -1%) PH III...

Credit Suisse thinks investors are overlooking the potential of Merck's (MRK -1%) PH III osteoporosis drug odanacatib. The firm says it expects increased focus on it with 2 interim efficacy reports expected this year, and raises its 2020 estimate for the drug to $1.1B from $350M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|